Pinealon

Pinealon Investigational International

Also known as: EDR tripeptide (Glu-Asp-Arg)
Category: Cognitive & Neurological Support — Peptide Bioregulator

What it is. Pinealon is a synthetic tripeptide—glutamate-aspartate-arginine—developed by Professor Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the family of short peptides that program terms "bioregulators," designed to target specific tissues; Pinealon is the analog aimed at pineal gland and brain cortex tissue. Its ultra-short structure is claimed to give it better stability and tissue penetration than the larger polypeptide preparations it was derived from.

The proposed mechanism, stated honestly. The Khavinson hypothesis is that tissue-specific short peptides can enter cells, interact with DNA sequences, and regulate gene expression—in Pinealon's case, activating expression of proteins associated with neuronal activity and reducing the intensity of neuronal cell death. Russian literature describes applications in cognitive support after brain injury, stroke, or neurosurgery, and in maintaining mental performance in older adults. It is worth stating plainly: the bioregulator hypothesis remains outside mainstream Western pharmacology, and the supporting literature comes overwhelmingly from one research ecosystem.

Where this belongs in a clinical conversation. Pinealon is not FDA-approved. Protocols vary between Russian sources and research vendors, and no standardized Western dosing exists. This is not an ordinary clinic-menu compound—it is best discussed with patients as an educational example of where the science is exploring, rather than as a routine therapy. Cautions include psychiatric instability, and grey-market sourcing is a genuine risk given the vendor landscape. Effects, if present, are described as subtle and gradual over weeks to months. Anyone with active neurological or psychiatric disease needs proper evaluation and referral first—that is the defensible and necessary step.